Anti-inflammatory therapy of atherosclerotic cardiovascular diseases
Article Sidebar
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Main Article Content
https://orcid.org/0009-0001-3780-3179
Abstract
In primary prevention studies, inflammation and hyperlipidemia predicted future cardiovascular events with similar accuracy. These initial epidemiological data eventually led to clinical trials that demonstrated that anti-inflammatory agents can significantly reduce the incidence of cardiovascular events without altering blood lipids. As lipid-lowering therapy has become more effective, inflammation has emerged as an important source of residual cardiovascular risk. These data are important in selecting additional therapies to reduce cardiovascular risk because they suggest that anti-inflammatory therapies are not yet fully utilized in clinical care and that focusing solely on lowering atherogenic lipids is unlikely to eliminate all vascular risk. This issue has gained more relevance since low-dose colchicine became the first anti-inflammatory agent approved by the US Food and Drug Administration for use as an adjunctive therapy to reduce the risk of recurrent myocardial infarction, stroke, coronary revascularization, and cardiovascular death. Recent evidence suggests that inflammatory mechanisms have not yet been fully exploited for the benefit of the patient.
Article Details
Keywords:
References
Soehnlein O, Libby P. Targeting inflammation in atherosclerosis-from experimental insights to the clinic. Nat. Rev. Drug Discov. 2021;20:589-610. https://doi.org/10.1038/s41573-021-00198-1
Roy P, Orecchioni M, Ley K. How the immune system shapes atherosclerosis: roles of innate and adaptive immunity. Nat Rev Immunol. 2022. [Online ahead of print] https://doi.org/10.1038/s41577-021-00584-1
Wolf D, Ley K. Immunity and Inflammation in Atherosclerosis. Circ Res. 2019;124:315-327. https://doi.org/10.1161/circresaha.118.313591
Fernandez DM, Rahman AH, Fernandez NF, Chudnovskiy A, Amir ED. Single-cell immune landscape of human atherosclerotic plaques. Nat Med. 2019;25:1576-1588. https://doi.org/10.1038/s41591-019-0590-4
Santos-Zas I, Lemarié J, Zlatanova I, Cachanado M, Seghezzi JC, Benamer H, Goube P, Vandestienne M, Cohen R, Ezzo M, et al. Cytotoxic CD8+ T cells promote granzyme B-dependent adverse post-ischemic cardiac remodeling. Nat Commun. 2021;12:1483. https://doi.org/10.1038/s41467-021-21737-9
Zhao TX, Sriranjan RS, Tuong ZK, Lu Y, Sage AP, Nus M, Hubsch A, Kaloyirou F, Vamvaka E, Helmy J, et al. Regulatory T-cell response to low-dose interleukin-2 in ischemic heart disease. NEJM Evidence. 2022;1:EVIDoa2100009. https://doi.org/10.1056/EVIDoa2100009
Fernandez DM, Rahman AH, Fernandez NF, Chudnovskiy A, Amir ED, Amadori L, Khan NS, Wong CK, Shamailova R, Hill CA, et al. Single-cell immune landscape of human atherosclerotic plaques. Nat Med. 2019;25:1576-1588. https://doi.org/10.1038/s41591-019-0590-4
Cochain C, Koch M, Chaudhari SM, Busch M, Pelisek J, Boon L, Zernecke A. CD8+ T cells regulate monopoiesis and circulating Ly6C high monocyte levels in atherosclerosis in mice. Circ Res. 2015;117:244-253. https://doi.org/10.1161/CIRCRESAHA.117.304611
Santos-Zas I, Lemarié J, Tedgui A, Ait-Oufella H. Adaptive immune responses contribute to post-ischemic cardiac remodeling. Front Cardiovasc Med. 2019;5:198. https://doi.org/10.3389/fcvm.2018.00198
Santos-Zas I, Lemarié J, Zlatanova I, Cachanado M, Seghezzi JC, Benamer H, Goube P, Vandestienne M, Cohen R, Ezzo M, et al. Cytotoxic CD8+ T cells promote granzyme B-dependent adverse post-ischemic cardiac remodeling. Nat Commun. 2021;12:1483. https://doi.org/10.1038/s41467-021-21737-9
Porsch F, Mallat Z, Binder CJ. Humoral immunity in atherosclerosis and myocardial infarction: from B cells to antibodies. Cardiovasc Res. 2021;117:2544-2562. https://doi.org/10.1093/cvr/cvab285
Taleb A, Willeit P, Amir S, Perkmann T, Kozma MO, Watzenböck ML, Binder CJ, Witztum JL, Tsimikas S. High immunoglobulin-M levels to oxidation-specific epitopes are associated with lower risk of acute myocardial infarction. J Lipid Res. 2023;64:100391. https://doi.org/10.1016/j.jlr.2023.100391
Ait-Oufella H, Herbin O, Bouaziz JD, Binder CJ, Uyttenhove C, Laurans L, Taleb S, Van Vré E, Esposito B, Vilar J, et al. B cell depletion reduces the development of atherosclerosis in mice. J Exp Med. 2010;207:1579-1587. https://doi.org/10.1084/jem.20100155
Zouggari Y, Ait-Oufella H, Bonnin P, Simon T, Sage AP, Guérin C, Vilar J, Caligiuri G, Tsiantoulas D, Laurans L, et al. B lymphocytes trigger monocyte mobilization and impair heart function after acute myocardial infarction. Nat Med. 2013;19:1273-1280. https://doi.org/10.1038/nm.3284
Farina CJ, Davidson MH, Shah PK, Stark C, Lu W, Shirodaria C, Wright T, Antoniades CA, Nilsson J, Mehta NN. Inhibition of oxidized low-density lipoprotein with orticumab inhibits coronary inflammation and reduces residual inflammatory risk in psoriasis: a pilot randomized, double-blind placebo-controlled trial. Cardiovasc Res. 2024;120:678-680. https://doi.org/10.1093/cvr/cvae057
Roy P, Ali AJ, Kobiyama K, Ghosheh Y, Ley K. Opportunities for an atherosclerosis vaccine: from mice to humans. Vaccine. 2020;38:4495-4506. https://doi.org/10.1016/j.vaccine.2019.12.039
Hansson GK, Libby P, Tabas I. Inflammation and plaque vulnerability. J Intern Med. 2015;278:483-493. https://doi.org/10.1111/joim.12406
Han J-l, Song Y-x, Yao W-j, Zhou J, Du Y, Xu T. Follicle-stimulating hormone provokes macrophages to secrete IL-1β contributing to atherosclerosis progression. J Immunol. 2023;210:25-32. https://doi.org/10.4049/jimmunol.2200475
Liberale L, Montecucco F, Schwarz L, Lüscher TF, Camici GG. Inflammation and cardiovascular diseases: lessons from seminal clinical trials. Cardiovasc Res. 2021;117:411-22. https://doi.org/10.1093/cvr/cvaa211
Galozzi P, Baggio C, Bindoli S, Oliviero F, Sfriso P. Development and role in therapy of canakinumab in adult-onset still’s. Front Pharmacol. 2018;9:1074. https://doi.org/10.3389/fphar.2018.01074
Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119-31. https://doi.org/10.1056/nejmoa1707914
Everett BM, Cornel JH, Lainscak M, Anker SD, Abbate A, et al. Anti-inflammatory therapy with canakinumab for the prevention of hospitalization for heart failure. Circulation. 2019;139:1289-1299. https://doi.org/10.1161/circulationaha.118.038010
Ruiz-Limon P, Ortega R, de la Rosa IA, Del Carmen Abalos-Aguilera M, Perez-Sanchez C, et al. Tocilizumab improves the proatherothrombotic profile of rheumatoid arthritis patients modulating endothelial dysfunction, NETosis, and inflammation. Transl Res. 2017;83:87-103. https://doi.org/10.1016/j.trsl.2016.12.003
Broch K, Anstensrud AK, Woxholt S, Sharma K, Tøllefsen IM, et al. Randomized Trial of Interleukin-6 Receptor Inhibition in Patients With Acute ST-Segment Elevation Myocardial Infarction. J Am Coll Cardiol. 2021;77:1845-1855. https://doi.org/10.1016/j.jacc.2021.02.049
Pergola PE, Devalaraja M, Fishbane S, Chonchol M, Mathur VS. Ziltivekimab for treatment of anemia of inflammation in patients on hemodialysis: results from a phase 1/2 multicenter, randomized, double-blind, placebo-controlled trial. J Am Soc Nephrol. 2021;32:211-222. https://doi.org/10.1681/asn.2020050595
Liberale L, Montecucco F, Schwarz L, Lüscher TF, Camici GG. Inflammation and cardiovascular diseases: lessons from seminal clinical trials. Cardiovasc Res. 2021;117:411-22. https://doi.org/10.1093/cvr/cvaa211
Silvis MJ, Fiolet AT, Opstal TS, Dekker M, Suquilanda D, et al. Colchicine reduces extracellular vesicle NLRP3 inflammasome protein levels in chronic coronary disease: a LoDoCo2 biomarker substudy. Atherosclerosis. 2021;334:93-100. https://doi.org/10.1016/j.atherosclerosis.2021.08.005
Fiolet ATL, Opstal TSJ, Mosterd A, Eikelboom JW, Jolly SS, Keech AC, Kelly P, Tong DC, Layland J, Nidorf SM, et al. Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials. Eur Heart J. 2021;42:2765-2775. https://doi.org/10.1093/eurheartj/ehab115
Samuel M, Tardif JC, Bouabdallaoui N, Khairy P, Dubé MP, Blondeau L, Guertin MC. Colchicine for secondary prevention of cardiovascular disease: a systematic review and meta-analysis of randomized controlled trials. Can J Cardiol. 2021;37:776-785. https://doi.org/10.1016/j.cjca.2020.10.006J.-
Bouabdallaoui N, Tardif J-C, Waters DD, Pinto FJ, Maggioni AP, et al. Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). Eur Heart J. 2020;41:4092-4099. https://doi.org/10.1093/eurheartj/ehaa659
Tong DC, Quinn S, Nasis A, Hiew C, Roberts-Thomson P, et al. Colchicine in Patients with Acute Coronary Syndrome. Circulation. 2020;142:1890-1900. https://doi.org/10.1161/circulationaha.120.050771
D’Entremont M-A, Lee SF, Mian R, Kedev S, Montalescot G, Cornel JH, et al. Design and rationale of the CLEAR SYNERGY (OASIS 9) trial: A 2x2 factorial randomized controlled trial of colchicine versus placebo and spironolactone vs placebo in patients with myocardial infarction. Am Heart J. 2024;275:173-182. https://doi.org/10.1016/j.ahj.2024.06.007
Carnicelli AP, Mentz RJ. Sodium-glucose Cotransporter 2 Inhibitors in Patients with Heart Failure with Reduced Ejection Fraction: the Heart and Kidney Working Better Together. Am Heart Assoc. 2021;322-325. https://doi.org/10.1161/circulationaha.120.052048
La Grotta R, de Candia P, Olivieri F, Matacchione G, Giuliani A, et al. Anti-inflammatory effect of SGLT-2 inhibitors via uric acid and insulin. CMLS. 2022;79:273. https://doi.org/10.1007/s00018-022-04289-z
Theofilis P , Sagris M, Oikonomou E, Antonopoulos AS, Siasos G. et al. The impact of SGLT2 inhibitors on inflammation: a systematic review and meta-analysis of studies in rodents. Int Immunopharm. 2022;111:109080. https://doi.org/10.1016/j.intimp.2022.109080
Kondo H, Akoumianakis I, Badi I, Akawi N, Kotanidis CP. et al. Effects of canagliflozin on human myocardial redox signalling: clinical implications. Eur Heart J. 2021;42:4947-4960. https://doi.org/10.1093/eurheartj/ehab420
Charles‐Schoeman C, Lee Y-Yin, Shahbazian A, Wang X, Elashoff D, et al. Improvement of high-density lipoprotein function in patients with early rheumatoid arthritis treated with methotrexate monotherapy or combination therapies in a randomized controlled trial. Arthritis Rheumatol. 2017;9:46-57. https://doi.org/10.1002/art.39833
Hjeltnes G, Hollan I, Førre O, Wiik A, Lyberg T, et al. Serum levels of lipoprotein (a) and E-selectin are reduced in rheumatoid arthritis patients treated with methotrexate or methotrexate in combination with TNF-α-inhibitor. Clin Exp Rheumatol. 2012;31:415-421. https://doi.org/10.3899/jrheum.111401
Ridker PM, Everett BM, Pradhan A, MacFadyen JG, Solomon D, et al. Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. N Engl J Med. 2019;380:752-762. https://doi.org/10.1056/nejmoa1809798
Singh TP, Skalina T, Nour D, Murali A, Morrison S, et al. A meta-analysis of the efficacy of allopurinol in reducing the incidence of myocardial infarction following coronary artery bypass grafting. BMC Cardiovasc Disord. 2018;18:1-9. https://doi.org/10.1186/s12872-018-0881-6
Guedes M, Esperança A, Pereira AC, Rego C. What is the effect on cardiovascular events of reducing hyperuricemia with allopurinol? An evidence-based review. Rev Port Cardiol. 2014;33:727-732. https://doi.org/10.1016/j.repce.2014.06.003
Struthers A, Shearer F. Allopurinol: novel indications in cardiovascular disease. Heart. 2012;98:1543-1545. https://doi.org/10.1136/heartjnl-2012-302249
Noman A, Ang DS, Ogston S, Lang CC, Struthers AD. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet. 2010;375:2161-2167. https://doi.org/10.1016/s0140-6736(10)60391-1
Antonopoulos AS, Papanikolaou Е, Vogiatzi G, Oikonomou E, Tousoulis D. Anti-inflammatory agents in peripheral arterial disease. Curr Opin Pharm. 2018;39:1-8. https://doi.org/10.1016/j.coph.2017.11.001
Casella IB, Presti C. A new era of medical therapy for peripheral artery disease. J Vasc Bras. 2020;19:e20190056. https://doi.org/10.1590/1677-5449.190056
Silverstein RL. PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Goes “DAMP”. Circulation. 2021;143:62-64. https://doi.org/10.1161/circulationaha.120.051940
Walley KR, Thain KR, Russell JA, Reilly MP, Meyer NJ. PCSK9 is a critical regulator of the innate immune response and septic shock outcome. Sci Transl Med. 2014;6:258ra143. https://doi.org/10.1126/scitranslmed.3008782
Momtazi-Borojeni AA, Jaafari MR, Afshar M, Banach M, Sahebkar A. PCSK9 immunization using nanoliposomes: preventive efficacy against hypercholesterolemia and atherosclerosis. Arch Med Sci. 2021;17:1365-1377. https://doi.org/10.5114/aoms/133885
Casula M, Olmastroni E, Boccalari MT, Tragni E, Pirillo A, et al. Cardiovascular events with PCSK9 inhibitors: an updated meta-analysis of randomised controlled trials. Pharm Res. 2019;143:143-150. https://doi.org/10.1016/j.phrs.2019.03.021
Oesterle A, Laufs U, Liao JK. Pleiotropic Effects of Statins on the Cardiovascular System. Circ Res. 2017;120:229-243. https://doi.org/10.1161/circresaha.116.308537
Niu Y, Bai N, Ma Y, Zhong P-Y, Shang Y-S, Wang Z.L. Safety and efficacy of anti-inflammatory therapy in patients with coronary artery disease: A systematic review and meta-analysis. BMC Cardiovasc Disord. 2022;22:84. https://doi.org/10.1186/s12872-022-02525-9
Kwon O, Kang S-J, Kang SH, Lee PH, Yun S-C, et al. Relationship Between Serum Inflammatory Marker Levels and the Dynamic Changes in Coronary Plaque Characteristics After Statin Therapy. Circ Cardiovasc Imaging. 2017;10: e005934. https://doi.org/10.1161/circimaging.116.005934
Hellberga S, Sippolaa S, Liljenbäckab H, et al. Effects of atorvastatin and diet interventions on atherosclerotic plaque inflammation and [18F]FDG uptake in Ldlr−/−Apob100/100 mice. Atherosclerosis. 2017;263:369-376. https://doi.org/10.1016/j.atherosclerosis.2017.04.004
Puri R, Nissen SE, Shao M, et al. Impact of Baseline Lipoprotein and C-Reactive Protein Levels on Coronary Atheroma Regression Following High-Intensity Statin Therapy. Am J Cardiology. 2014;114(10):1465-1472. https://doi.org/10.1016/j.amjcard.2014.08.009